Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 2006

Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
Cattedra di Ematologia, Università Tor Vergata, Ospedale S Eugenio, Via Fiume Giallo, 430 MA, 00144 Roma, Rome, Italy.

The clinical course of B-cell chronic lymphocytic leukemia (B-CLL) is variable, and novel biologic parameters need to be added to the clinical staging systems to predict an indolent or aggressive outcome. We investigated the 70-kDa zeta-associated protein (ZAP-70), CD38, soluble CD23 (sCD23), and cytogenetics in 289 patients with B-CLL. Both a shorter progression-free survival (PFS) and overall survival (OS) were observed in ZAP-70(+) (P < .001), in CD38(+) (P < .001) and in sCD23(+) patients (P < .001 and P = .013, respectively). ZAP-70(+)CD38(+) or ZAP-70(+) patients with an unmutated IgV(H) status showed both a shorter PFS (P < .001) and OS (P < .001 and P < .001, respectively) as compared with ZAP-70(-)/CD38(-) or ZAP-70(-) patients with mutated IgV(H) genes. Discordant patients showed an intermediate outcome. Note, ZAP-70(+) patients even if CD38(-) or mutated showed a shorter PFS, whereas ZAP-70(-) patients even if CD38(+) or unmutated had a longer PFS. Furthermore, ZAP-70 positivity was associated with a shorter PFS both within normal karyotype (P < .001) and within the poor-risk cytogenetic subset (P = .02). The predictive value of ZAP-70 expression was confirmed in multivariate analysis. Thus, ZAP-70 protein determined by flow cytometry improves the prognostic significance of cytogenetics and appears to be a better predictor of outcomes than IgV(H) gene mutational status. On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70(+) patients.

UI MeSH Term Description Entries
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
May 2009, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
December 2006, Vnitrni lekarstvi,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
January 2008, Clinical advances in hematology & oncology : H&O,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
April 2006, Zhongguo shi yan xue ye xue za zhi,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
April 2006, Annals of oncology : official journal of the European Society for Medical Oncology,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
January 2008, Voprosy onkologii,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
January 2006, The Egyptian journal of immunology,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
September 2007, Best practice & research. Clinical haematology,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
July 2003, The New England journal of medicine,
Maria Ilaria Del Principe, and Giovanni Del Poeta, and Francesco Buccisano, and Luca Maurillo, and Adriano Venditti, and Antonella Zucchetto, and Rita Marini, and Pasquale Niscola, and Maria Antonietta Irno Consalvo, and Carla Mazzone, and Licia Ottaviani, and Paola Panetta, and Antonio Bruno, and Riccardo Bomben, and Giovanna Suppo, and Massimo Degan, and Valter Gattei, and Paolo de Fabritiis, and Maria Cantonetti, and Francesco Lo Coco, and Domenico Del Principe, and Sergio Amadori
July 2006, Cytometry. Part B, Clinical cytometry,
Copied contents to your clipboard!